Sex-specific association of time-varying haemoglobin values with mortality in incident dialysis patients.
暂无分享,去创建一个
F. Kronenberg | C. Lamina | K. Lhotta | E. Zitt | U. Neyer | Gisela Sturm | Friederike Lins | Otto Freistätter
[1] A. Covic,et al. The safety and efficacy of intravenous ferric carboxymaltose in anaemic patients undergoing haemodialysis: a multi-centre, open-label, clinical study , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[2] F. Schmidt. Meta-Analysis , 2008 .
[3] R. Foley,et al. Hemoglobin level variability: associations with mortality. , 2008, Clinical journal of the American Society of Nephrology : CJASN.
[4] M. Joffe,et al. Hemoglobin variability and mortality in ESRD. , 2007, Journal of the American Society of Nephrology : JASN.
[5] Kdoqi. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. , 2007 .
[6] H. Krum,et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis , 2007, The Lancet.
[7] J. Berns,et al. KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for anemia in chronic kidney disease: 2007 update of hemoglobin target. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[8] H. Burger,et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. , 2006, The New England journal of medicine.
[9] Huiman Barnhart,et al. Correction of anemia with epoetin alfa in chronic kidney disease. , 2006, The New England journal of medicine.
[10] R. Foley,et al. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. , 2006, Clinical journal of the American Society of Nephrology : CJASN.
[11] F. Kronenberg,et al. Carotid plaques and their predictive value for cardiovascular disease and all-cause mortality in hemodialysis patients considering renal transplantation: a decade follow-up. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[12] A. Levin,et al. Effect of early correction of anemia on the progression of CKD. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[13] S. Greenland,et al. Associations between changes in hemoglobin and administered erythropoiesis-stimulating agent and survival in hemodialysis patients. , 2006, Journal of the American Society of Nephrology : JASN.
[14] K. Kalantar-Zadeh,et al. Association of anemia with outcomes in men with moderate and severe chronic kidney disease. , 2006, Kidney international.
[15] L. Arab,et al. Evidence-based systematic literature review of hemoglobin/hematocrit and all-cause mortality in dialysis patients. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[16] P. Parfrey. Target hemoglobin level for EPO therapy in CKD. , 2006, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[17] A. Levin,et al. Sex, haemoglobin and kidney disease: new perspectives , 2005, European journal of clinical investigation.
[18] J. Craig,et al. Hypothesis versus association: the optimal hemoglobin target debate. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[19] J. Singer,et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. , 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[20] S. Fishbane,et al. Hemoglobin cycling in hemodialysis patients treated with recombinant human erythropoietin. , 2005, Kidney international.
[21] R. Foley,et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. , 2005, Journal of the American Society of Nephrology : JASN.
[22] M. Haugen,et al. Dietary intake of differently fed salmon; the influence on markers of human atherosclerosis , 2005, European journal of clinical investigation.
[23] Francesco Locatelli,et al. Anemia management and outcomes from 12 countries in the Dialysis Outcomes and Practice Patterns Study (DOPPS). , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[24] A. Collins,et al. Association of hematocrit value with cardiovascular morbidity and mortality in incident hemodialysis patients. , 2004, Kidney international.
[25] David Voss,et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. , 2004, Journal of the American Society of Nephrology : JASN.
[26] S. Fishbane,et al. Hemoglobin variability in epoetin-treated hemodialysis patients. , 2003, Kidney international.
[27] Eduardo Lacson,et al. The effects of higher hemoglobin levels on mortality and hospitalization in hemodialysis patients. , 2003, Kidney international.
[28] A. Christensson,et al. A randomized controlled trial of haemoglobin normalization with epoetin alfa in pre-dialysis and dialysis patients. , 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[29] J. Lazarus,et al. Effect of variability in anemia management on hemoglobin outcomes in ESRD. , 2003, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[30] L. Dworkin,et al. Residual renal function and mortality risk in hemodialysis patients. , 2001, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[31] A. Collins,et al. Impact of hematocrit on morbidity and mortality. , 2000, Seminars in nephrology.
[32] A. Levin,et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. , 2000, Kidney international.
[33] Avid,et al. THE EFFECTS OF NORMAL AS COMPARED WITH LOW HEMATOCRIT VALUES IN PATIENTS WITH CARDIAC DISEASE WHO ARE RECEIVING HEMODIALYSIS AND EPOETIN , 2000 .
[34] J. Singer,et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. , 1999, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[35] A. Collins,et al. Hematocrit levels and hospitalization risks in hemodialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.
[36] A. Collins,et al. Hematocrit level and associated mortality in hemodialysis patients. , 1999, Journal of the American Society of Nephrology : JASN.
[37] Brian D. Marx,et al. Generalized Linear Regression on Sampled Signals and Curves: A P-Spline Approach , 1999, Technometrics.
[38] David C. Murray,et al. The impact of anemia on cardiomyopathy, morbidity, and and mortality in end-stage renal disease. , 1996, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[39] W. Schobersberger,et al. Red cell oxygen transport in man in relation to gender and age , 1989, Mechanisms of Ageing and Development.